Novacyt: Yourgene officially delisted in London
Following an application to the London Stock Exchange, the listing of Yourgene shares on the London Stock Exchange was cancelled this Monday, with effect from 7:00 am.
The £16.7 million (approx. €19.5 million) acquisition of Yourgene Health, a British specialist in molecular diagnostics, should enable Novacyt to diversify, notably into non-invasive prenatal screening devices, for Down syndrome (trisomy 21) for example.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction